Navigation Links
Pain Medication OTC Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld
Date:5/15/2013

Melbourne, Australia (PRWEB) May 16, 2013

The Pain Medication OTC Manufacturing industry manufactures pharmaceutical products that focus on pain relief and are available without a doctor's permission. As a country with a high awareness of medication and self-medication uses, domestic demand for OTC pain medication has remained healthy over the past five years. This is despite a cautious consumer environment in which consumers have attempted to focus spending on high-value items.

Local manufacturing operations have struggled to benefit from this trend. According to IBISWorld industry analyst Craig Shulman, “global pharmaceutical manufacturing has shifted production towards Asia, where labour is cheaper and the plants are larger, leading to substantial increases in economies of scale.” With these jumps in production capacity, import competition has increased substantially. Australian operations have to deal with higher wage costs. Consequently, this competition is putting pressure on industry profit margins. IBISWorld expects revenue to decrease at an annualised rate of 2.0% over the five years to 2012-13. In 2012-13, revenue is expected to decline 3.3% to reach $834.4 million.

Over the next five years, these trends are expected to continue. Import competition is expected to provide a strong challenge to local manufacturers. “Global pharmaceutical manufacturers are expected to increase their foothold on the global OTC market, as they take advantage of the growing popularity of OTC medication in developing countries and thus improve their global economies of scale,” says Shulman. These growing markets are also new opportunities for Australian manufacturers, which will still have to combat cheaper production methods in these countries as well.

The Pain Medication OTC Manufacturing industry in Australia exhibits a medium level of market share concentration. The top two companies are Pfizer Australia Holdings Pty Limited and GlaxoSmithKline Holdings Pty Ltd.

Over the next five years, many patents are set to expire, with more products and players expected to enter the Pain Medication OTC Manufacturing industry. Established players are likely to extend the life of their former prescription medications by attempting to shift it into the OTC market, pending confirmation from regulators that the products are safe for widespread use without a doctor's prescription. If this is successful, generic brands are expected to follow soon after.

For more information, visit IBISWorld’s Pain Medication OTC Manufacturing report in Australia industry page.

Follow IBISWorld on Twitter: http://twitter.com/#!/ibisworldau

IBISWorld Industry Report Key Topics

Companies in this industry research and develop medicines with pain-relieving, anti-inflammatory and other effects. Products manufactured by the industry are available without a prescription in various OTC locations.

Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
International Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Basis of Competition
Barriers to Entry
Industry Globalisation
Major Companies
Operating Conditions
Capital Intensity
Technology & Systems
Revenue Volatility
Regulation & Policy
Industry Assistance
Key Statistics
Industry Data
Annual Change
Key Ratios

About IBISWorld Inc.
Recognised as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every Australian industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Melbourne, IBISWorld serves a range of business, professional service and government organisations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com.au or call (03) 9655 3886.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10735532.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Forgoing Medication, for Babys Sake
2. Parents poor math skills may lead to medication errors
3. Reducing off-label use of antipsychotic medications may save money
4. Common acne medication doubles risk of eye infection
5. Misuse of over-the-counter pain medication is potential health threat
6. Genes predict if medication can help you quit smoking
7. Acne Medication May Raise Risk of Eye Infections
8. New delivery method improves efficacy of 2 common Parkinsons disease medications
9. Mount Sinai researcher finds timing of ADHD medication affect academic progress
10. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
11. Physicians dont adequately monitor patients medication adherence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: